Standard BioTools Inc. (LAB)
NASDAQ: LAB · Real-Time Price · USD
0.6226
+0.0065 (1.06%)
Oct 28, 2026, 10:25 AM EDT - Market open
Standard BioTools Revenue
Standard BioTools had revenue of $20.10M in the quarter ending June 30, 2026, a decrease of -7.62%. This brings the company's total for the last twelve months to $84.60M, up 249.98% year-over-year. In the year 2025, Standard BioTools had annual revenue of $85.33M, down -6.24%. That makes Standard BioTools the 23,934th largest company in the world by revenue and 3,399th in the United States.
Revenue (ttm)
$84.60M
Revenue Growth
+249.98%
P/S Ratio
2.86
Revenue / Employee
$217,473
Employees
389
Market Cap
244.42M
Revenue by Geography
- United States 28.40M 33.3%
- Emea Excl. Sweden 27.39M 32.1%
- China 10.90M 12.8%
- Sweden 8.60M 10.1%
- Asia-Pacific (Excl. China) 7.88M 9.2%
- Americas Excl. United States 2.16M 2.5%
Fiscal year ended Dec 31, 2025 See the full Standard BioTools breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 85.33M | -5.68M | -6.24% |
| Dec 31, 2024 | 91.01M | -15.33M | -14.42% |
| Dec 31, 2023 | 106.34M | 8.39M | 8.57% |
| Dec 31, 2022 | 97.95M | -32.63M | -24.99% |
| Dec 31, 2021 | 130.58M | -7.56M | -5.47% |
| Dec 31, 2020 | 138.14M | 20.90M | 17.83% |
| Dec 31, 2019 | 117.24M | 4.28M | 3.79% |
| Dec 31, 2018 | 112.96M | 11.03M | 10.82% |
| Dec 31, 2017 | 101.94M | -2.51M | -2.40% |
| Dec 31, 2016 | 104.45M | -10.27M | -8.95% |
| Dec 31, 2015 | 114.71M | -1.74M | -1.50% |
| Dec 31, 2014 | 116.46M | 45.27M | 63.60% |
| Dec 31, 2013 | 71.18M | 18.85M | 36.02% |
| Dec 31, 2012 | 52.33M | 9.47M | 22.09% |
| Dec 31, 2011 | 42.87M | 9.31M | 27.73% |
| Dec 31, 2010 | 33.56M | 8.15M | 32.06% |
| Dec 31, 2009 | 25.41M | 10.07M | 65.58% |
| Dec 27, 2008 | 15.35M | 8.07M | 110.96% |
| Dec 29, 2007 | 7.28M | 877.00K | 13.71% |
| Dec 31, 2006 | 6.40M | -1.28M | -16.63% |
| Dec 31, 2005 | 7.67M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Inogen | 354.30M |
| Treace Medical Concepts | 205.31M |
| InfuSystem Holdings | 143.34M |
| RxSight | 127.58M |
| Electromed | 73.78M |
| Mobia Medical | 45.28M |
| TriSalus Life Sciences | 45.08M |
| ClearPoint Neuro | 42.28M |
LAB News
- 22 days ago - Standard BioTools to sell Microfluidics business to Archimed, terms undisclosed - TheFly
- 22 days ago - Standard BioTools Announces Agreement to Sell Microfluidics Business to ARCHIMED - GlobeNewsWire
- 27 days ago - Standard BioTools provides update on sale of mass cytometry business - TheFly
- 27 days ago - Standard BioTools Provides Update on Sale of Mass Cytometry Business - GlobeNewsWire
- 2 months ago - Standard BioTools Reports Second Quarter 2026 Financial Results - GlobeNewsWire
- 2 months ago - Standard BioTools Earnings release: Q2 2026 - Filings
- 2 months ago - Standard BioTools Quarterly report: Q2 2026 - Filings
- 3 months ago - Standard BioTools to sell Mass Cytometry business to Multiplex Bio for $10M - TheFly